‘I wouldn’t call it a blip’: Biotech IPOs here to stay after another record-breaking listing Read more →

Ipsen R&D chief on pipeline discipline, partnerships and 2026 milestones Read more →

Guardant Health nabs FDA test approval to find patients for Boehringer’s new cancer drug Read more →